NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
NR 566 MIDTERM EXAM (2026/2027)
CHAMBERLAIN ADVANCED PHARMACOLOGY -
ACTUAL QUESTIONS AND ANSWERS
Advanced Pharmacology for Care of the Family - Midterm Examination Preparation with Verified
Answers
125 Questions | 8 Sections | Weeks 1-4 Content Coverage with Detailed Pharmacology Rationales
Cognitive Mix: ~30% Recall • ~50% Application • ~20% Analysis • ~75% Scenario-Based / ~25% Direct Recall
Instructions: For each question, select the single best answer. Each question provides four options (A–D); the correct option
is marked [CORRECT]. Detailed advanced pharmacology rationales explain why the correct answer is right and why the
distractors are wrong, including pharmacokinetic principles, pharmacodynamic mechanisms, clinical guidelines, and
patient-specific considerations. Use this packet for midterm preparation and self-assessment.
# Section Q Range Count
1 Pharmacokinetics and Pharmacodynamics Foundations Q1-Q14 14
2 Prescriptive Authority, Legal, and Ethical Considerations Q15-Q26 12
3 Cardiovascular Pharmacology Q27-Q46 20
4 Endocrine Pharmacology Q47-Q62 16
5 Respiratory and Allergy Pharmacology Q63-Q76 14
6 Anti-Infective Pharmacology Q77-Q94 18
7 Pain Management and Anti-Inflammatory Agents Q95-Q108 14
8 Special Populations and Prescribing Considerations Q109-Q125 17
TOTAL Q1-Q125 125
Section 1: Pharmacokinetics and Pharmacodynamics Foundations
Questions Q1-Q14 | 14 Questions
Q1. A 68-year-old patient receives an oral dose of propranolol. Which pharmacokinetic process is most
directly responsible for the substantial reduction in bioavailability compared with intravenous
administration?
A. Renal tubular secretion before systemic circulation
B. First-pass hepatic metabolism by the liver before reaching systemic circulation [CORRECT]
C. Plasma protein binding in the systemic circulation
D. Biliary recirculation delaying absorption
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 1
,NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
Rationale: First-pass (presystemic) metabolism in the liver substantially reduces the bioavailability of oral
propranolol before it reaches systemic circulation. Renal secretion, protein binding, and enterohepatic
recirculation occur after systemic distribution. Drugs with extensive first-pass metabolism (e.g., propranolol,
morphine, verapamil) require higher oral doses than parenteral doses to achieve equivalent effect. Study note:
drugs with high first-pass effect are poor candidates for oral dosing in hepatic impairment.
Q2. A patient is started on a medication with a half-life of 24 hours. Assuming no loading dose,
approximately how long will it take to reach steady-state plasma concentration?
A. Approximately 12 hours
B. Approximately 24 hours
C. Approximately 4–5 half-lives, or about 96–120 hours [CORRECT]
D. Approximately 1 week to 10 days
Correct Answer: C
Rationale: Steady state is reached in approximately 4–5 half-lives regardless of dose. For a drug with a 24-hour
half-life, steady state takes ~96–120 hours (4–5 days). A loading dose can achieve therapeutic levels rapidly for
drugs with long half-lives (e.g., amiodarone, digoxin). Study note: this principle explains why digoxin loading is
used for rapid effect.
Q3. A drug has a narrow therapeutic index. Which statement best describes the clinical implication?
A. The drug can be dosed freely without monitoring.
B. The drug has a narrow margin between therapeutic and toxic doses; serum drug monitoring (e.g.,
trough levels) is required. [CORRECT]
C. The drug has no adverse effects.
D. The drug can be combined with any other medication safely.
Correct Answer: B
Rationale: A narrow therapeutic index means the toxic dose is close to the therapeutic dose, requiring serum
drug monitoring (e.g., vancomycin trough, digoxin level, phenytoin, lithium, warfarin INR). Examples include
digoxin, lithium, warfarin, phenytoin, aminoglycosides, and vancomycin. These drugs require careful dosing,
monitoring, and avoidance of interacting drugs. Study note: memorize the 'narrow TI' drug list for exam.
Q4. A patient who is a CYP2D6 poor metabolizer is prescribed codeine for post-operative pain. What is the
most likely clinical consequence?
A. Increased conversion to morphine with risk of respiratory depression
B. Reduced conversion to morphine with inadequate analgesia [CORRECT]
C. No change in effect
D. Immediate anaphylaxis
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 2
,NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
Rationale: Codeine is a prodrug converted to morphine by CYP2D6. Poor metabolizers produce little morphine
and experience inadequate analgesia. Conversely, ultra-rapid metabolizers (gene duplication) produce excess
morphine and are at risk of respiratory depression, which is why codeine is contraindicated in breastfeeding
women and children after tonsillectomy. This illustrates clinically actionable pharmacogenomics.
Q5. Which CYP450 enzyme is responsible for the majority of clinically significant drug-drug interactions,
including those involving many SSRIs, beta-blockers, and antiarrhythmics?
A. CYP3A4 [CORRECT]
B. CYP2D6
C. CYP2C9
D. CYP1A2
Correct Answer: A
Rationale: CYP3A4 metabolizes approximately 50% of clinically used drugs, including many statins, calcium
channel blockers, benzodiazepines, and macrolide antibiotics. Strong CYP3A4 inhibitors (e.g., ketoconazole,
clarithromycin, ritonavir, grapefruit juice) can markedly increase levels of substrate drugs (e.g., simvastatin) and
cause toxicity. CYP2D6 metabolizes codeine, tamoxifen, and many antidepressants; CYP2C9 metabolizes
warfarin and phenytoin.
Q6. A patient taking warfarin is started on amiodarone. The INR rises significantly within 2 weeks. Which
pharmacokinetic mechanism best explains this interaction?
A. Amiodarone induces CYP2C9, increasing warfarin metabolism.
B. Amiodarone inhibits CYP2C9 (and 3A4), reducing warfarin clearance and increasing INR.
[CORRECT]
C. Amiodarone decreases warfarin protein binding.
D. Amiodarone accelerates warfarin absorption.
Correct Answer: B
Rationale: Amiodarone is a potent CYP2C9 inhibitor; because warfarin (especially the S-enantiomer) is
metabolized by CYP2C9, clearance falls and INR rises. Anticipated warfarin dose reduction (typically 25–50%)
and frequent INR monitoring are required when amiodarone is added. Other CYP2C9 inhibitors include
fluconazole, metronidazole, TMP-SMX, and amiodarone.
Q7. Which medication class produces effects through competitive antagonism at beta-1 receptors primarily
in the heart, reducing heart rate and myocardial oxygen demand?
A. Calcium channel blockers (dihydropyridine)
B. Cardioselective beta-1 blockers (e.g., metoprolol, atenolol) [CORRECT]
C. Alpha-1 blockers (e.g., terazosin)
D. ACE inhibitors
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 3
, NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
Rationale: Cardioselective beta-1 blockers (metoprolol, atenolol, bisoprolol) competitively antagonize beta-1
receptors in the heart, reducing heart rate, contractility, and myocardial oxygen demand. They are first-line
post-MI and in HFrEF. Non-selective agents (propranolol) also block beta-2 and are avoided in asthma/COPD.
Cardioselectivity is dose-dependent and lost at higher doses.
Q8. A drug that binds to a receptor and produces a maximal response is best described as a:
A. Partial agonist
B. Full agonist [CORRECT]
C. Competitive antagonist
D. Inverse agonist
Correct Answer: B
Rationale: A full agonist binds the receptor and produces the maximal possible response (intrinsic efficacy = 1).
A partial agonist produces a submaximal response even at full receptor occupancy (e.g., buprenorphine at mu
receptors). A competitive antagonist blocks the receptor without intrinsic activity; an inverse agonist reduces
constitutive receptor activity below baseline.
Q9. Which statement correctly describes a partial agonist in clinical practice?
A. A partial agonist produces a maximal response greater than a full agonist.
B. A partial agonist produces a submaximal response at full receptor occupancy and can act as a
competitive antagonist in the presence of a full agonist (e.g., buprenorphine in opioid use disorder).
[CORRECT]
C. A partial agonist has no receptor affinity.
D. A partial agonist only binds to enzymes.
Correct Answer: B
Rationale: A partial agonist has receptor affinity but reduced intrinsic efficacy, producing submaximal
response. In the presence of a full agonist, it acts as a competitive antagonist. Buprenorphine is a partial mu
agonist used in opioid use disorder: it blunts withdrawal without producing the full euphoria of full agonists.
Varenicline (nicotinic partial agonist) is another example.
Q10. A 75-year-old patient with chronic kidney disease (eGFR 25 mL/min) is prescribed digoxin. Which
pharmacokinetic consideration is most accurate?
A. Loading dose should be increased.
B. Maintenance dose should be reduced (renally cleared drug) and serum levels monitored to avoid
toxicity. [CORRECT]
C. Half-life is shortened in renal failure.
D. Protein binding is increased in renal failure.
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 4
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
NR 566 MIDTERM EXAM (2026/2027)
CHAMBERLAIN ADVANCED PHARMACOLOGY -
ACTUAL QUESTIONS AND ANSWERS
Advanced Pharmacology for Care of the Family - Midterm Examination Preparation with Verified
Answers
125 Questions | 8 Sections | Weeks 1-4 Content Coverage with Detailed Pharmacology Rationales
Cognitive Mix: ~30% Recall • ~50% Application • ~20% Analysis • ~75% Scenario-Based / ~25% Direct Recall
Instructions: For each question, select the single best answer. Each question provides four options (A–D); the correct option
is marked [CORRECT]. Detailed advanced pharmacology rationales explain why the correct answer is right and why the
distractors are wrong, including pharmacokinetic principles, pharmacodynamic mechanisms, clinical guidelines, and
patient-specific considerations. Use this packet for midterm preparation and self-assessment.
# Section Q Range Count
1 Pharmacokinetics and Pharmacodynamics Foundations Q1-Q14 14
2 Prescriptive Authority, Legal, and Ethical Considerations Q15-Q26 12
3 Cardiovascular Pharmacology Q27-Q46 20
4 Endocrine Pharmacology Q47-Q62 16
5 Respiratory and Allergy Pharmacology Q63-Q76 14
6 Anti-Infective Pharmacology Q77-Q94 18
7 Pain Management and Anti-Inflammatory Agents Q95-Q108 14
8 Special Populations and Prescribing Considerations Q109-Q125 17
TOTAL Q1-Q125 125
Section 1: Pharmacokinetics and Pharmacodynamics Foundations
Questions Q1-Q14 | 14 Questions
Q1. A 68-year-old patient receives an oral dose of propranolol. Which pharmacokinetic process is most
directly responsible for the substantial reduction in bioavailability compared with intravenous
administration?
A. Renal tubular secretion before systemic circulation
B. First-pass hepatic metabolism by the liver before reaching systemic circulation [CORRECT]
C. Plasma protein binding in the systemic circulation
D. Biliary recirculation delaying absorption
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 1
,NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
Rationale: First-pass (presystemic) metabolism in the liver substantially reduces the bioavailability of oral
propranolol before it reaches systemic circulation. Renal secretion, protein binding, and enterohepatic
recirculation occur after systemic distribution. Drugs with extensive first-pass metabolism (e.g., propranolol,
morphine, verapamil) require higher oral doses than parenteral doses to achieve equivalent effect. Study note:
drugs with high first-pass effect are poor candidates for oral dosing in hepatic impairment.
Q2. A patient is started on a medication with a half-life of 24 hours. Assuming no loading dose,
approximately how long will it take to reach steady-state plasma concentration?
A. Approximately 12 hours
B. Approximately 24 hours
C. Approximately 4–5 half-lives, or about 96–120 hours [CORRECT]
D. Approximately 1 week to 10 days
Correct Answer: C
Rationale: Steady state is reached in approximately 4–5 half-lives regardless of dose. For a drug with a 24-hour
half-life, steady state takes ~96–120 hours (4–5 days). A loading dose can achieve therapeutic levels rapidly for
drugs with long half-lives (e.g., amiodarone, digoxin). Study note: this principle explains why digoxin loading is
used for rapid effect.
Q3. A drug has a narrow therapeutic index. Which statement best describes the clinical implication?
A. The drug can be dosed freely without monitoring.
B. The drug has a narrow margin between therapeutic and toxic doses; serum drug monitoring (e.g.,
trough levels) is required. [CORRECT]
C. The drug has no adverse effects.
D. The drug can be combined with any other medication safely.
Correct Answer: B
Rationale: A narrow therapeutic index means the toxic dose is close to the therapeutic dose, requiring serum
drug monitoring (e.g., vancomycin trough, digoxin level, phenytoin, lithium, warfarin INR). Examples include
digoxin, lithium, warfarin, phenytoin, aminoglycosides, and vancomycin. These drugs require careful dosing,
monitoring, and avoidance of interacting drugs. Study note: memorize the 'narrow TI' drug list for exam.
Q4. A patient who is a CYP2D6 poor metabolizer is prescribed codeine for post-operative pain. What is the
most likely clinical consequence?
A. Increased conversion to morphine with risk of respiratory depression
B. Reduced conversion to morphine with inadequate analgesia [CORRECT]
C. No change in effect
D. Immediate anaphylaxis
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 2
,NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
Rationale: Codeine is a prodrug converted to morphine by CYP2D6. Poor metabolizers produce little morphine
and experience inadequate analgesia. Conversely, ultra-rapid metabolizers (gene duplication) produce excess
morphine and are at risk of respiratory depression, which is why codeine is contraindicated in breastfeeding
women and children after tonsillectomy. This illustrates clinically actionable pharmacogenomics.
Q5. Which CYP450 enzyme is responsible for the majority of clinically significant drug-drug interactions,
including those involving many SSRIs, beta-blockers, and antiarrhythmics?
A. CYP3A4 [CORRECT]
B. CYP2D6
C. CYP2C9
D. CYP1A2
Correct Answer: A
Rationale: CYP3A4 metabolizes approximately 50% of clinically used drugs, including many statins, calcium
channel blockers, benzodiazepines, and macrolide antibiotics. Strong CYP3A4 inhibitors (e.g., ketoconazole,
clarithromycin, ritonavir, grapefruit juice) can markedly increase levels of substrate drugs (e.g., simvastatin) and
cause toxicity. CYP2D6 metabolizes codeine, tamoxifen, and many antidepressants; CYP2C9 metabolizes
warfarin and phenytoin.
Q6. A patient taking warfarin is started on amiodarone. The INR rises significantly within 2 weeks. Which
pharmacokinetic mechanism best explains this interaction?
A. Amiodarone induces CYP2C9, increasing warfarin metabolism.
B. Amiodarone inhibits CYP2C9 (and 3A4), reducing warfarin clearance and increasing INR.
[CORRECT]
C. Amiodarone decreases warfarin protein binding.
D. Amiodarone accelerates warfarin absorption.
Correct Answer: B
Rationale: Amiodarone is a potent CYP2C9 inhibitor; because warfarin (especially the S-enantiomer) is
metabolized by CYP2C9, clearance falls and INR rises. Anticipated warfarin dose reduction (typically 25–50%)
and frequent INR monitoring are required when amiodarone is added. Other CYP2C9 inhibitors include
fluconazole, metronidazole, TMP-SMX, and amiodarone.
Q7. Which medication class produces effects through competitive antagonism at beta-1 receptors primarily
in the heart, reducing heart rate and myocardial oxygen demand?
A. Calcium channel blockers (dihydropyridine)
B. Cardioselective beta-1 blockers (e.g., metoprolol, atenolol) [CORRECT]
C. Alpha-1 blockers (e.g., terazosin)
D. ACE inhibitors
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 3
, NR 566 - Advanced Pharmacology for Care of the Family Midterm Exam (2026/2027)
125 Questions | 8 Sections | Chamberlain Actual Questions and Answers
Rationale: Cardioselective beta-1 blockers (metoprolol, atenolol, bisoprolol) competitively antagonize beta-1
receptors in the heart, reducing heart rate, contractility, and myocardial oxygen demand. They are first-line
post-MI and in HFrEF. Non-selective agents (propranolol) also block beta-2 and are avoided in asthma/COPD.
Cardioselectivity is dose-dependent and lost at higher doses.
Q8. A drug that binds to a receptor and produces a maximal response is best described as a:
A. Partial agonist
B. Full agonist [CORRECT]
C. Competitive antagonist
D. Inverse agonist
Correct Answer: B
Rationale: A full agonist binds the receptor and produces the maximal possible response (intrinsic efficacy = 1).
A partial agonist produces a submaximal response even at full receptor occupancy (e.g., buprenorphine at mu
receptors). A competitive antagonist blocks the receptor without intrinsic activity; an inverse agonist reduces
constitutive receptor activity below baseline.
Q9. Which statement correctly describes a partial agonist in clinical practice?
A. A partial agonist produces a maximal response greater than a full agonist.
B. A partial agonist produces a submaximal response at full receptor occupancy and can act as a
competitive antagonist in the presence of a full agonist (e.g., buprenorphine in opioid use disorder).
[CORRECT]
C. A partial agonist has no receptor affinity.
D. A partial agonist only binds to enzymes.
Correct Answer: B
Rationale: A partial agonist has receptor affinity but reduced intrinsic efficacy, producing submaximal
response. In the presence of a full agonist, it acts as a competitive antagonist. Buprenorphine is a partial mu
agonist used in opioid use disorder: it blunts withdrawal without producing the full euphoria of full agonists.
Varenicline (nicotinic partial agonist) is another example.
Q10. A 75-year-old patient with chronic kidney disease (eGFR 25 mL/min) is prescribed digoxin. Which
pharmacokinetic consideration is most accurate?
A. Loading dose should be increased.
B. Maintenance dose should be reduced (renally cleared drug) and serum levels monitored to avoid
toxicity. [CORRECT]
C. Half-life is shortened in renal failure.
D. Protein binding is increased in renal failure.
Correct Answer: B
NR 566 - Advanced Pharmacology Midterm Chamberlain University - Weeks 1-4 Content Page 4
